Xcout Intel
Bugworks Research, Inc.
Bugworks Research Inc. is a clinical-stage biopharmaceutical company headquartered in Bangalore, India, developing novel therapeutics to combat antimicrobial resistance.
Subscribe to see Bugworks Research, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Bugworks Research, Inc. at a glance
Bugworks Research, Inc. is a biotech company headquartered in United States. Its most recent funding round raised $6.8M in February 2024. Xcout tracks 13 named people at Bugworks Research, Inc., including Anand Anandkumar (CEO & MD).
Bugworks Research, Inc. leadership
- Anand AnandkumarCEO & MD
- Balasubramanian VCOO
- Shahul HameedCSO
- Anand AnandkumarCo-Founder & Director
- Balasubramanian VCo-Founder & Director
- Santanu DattaCo-Founder & Director
7 more named people on record for Bugworks Research, Inc., with roles, board committees and tenure — see the full roster →
Bugworks Research, Inc. funding rounds
The 6 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $6.8M | — | |
| SEC Form D filing | $16M | — | |
| SEC Form D filing | $6.2M | — | |
| — | $7.5M | 4 named | |
| SEC Form D filing | $8.5M | — | |
| Series A | $9M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Bugworks Research, Inc. competitors
A few of Bugworks Research, Inc.'s closest competitors — see the full list of competitors and alternatives →
BioVersys AG is an award-winning, privately-owned Swiss pharmaceutical and biotech company headquartered in Basel, Switzerland, focused on the research and development of antibacterial treatments for drug-resistant bacterial infections.
AMR Bio is a clinical-stage biotechnology company headquartered in London, United Kingdom, focused on infection prevention and antimicrobial resistance. The company is dedicated to developing novel anti-infectives, including its Phase 3-ready, first-in-class topical antimicrobial candidate XF-73.
C3J Therapeutics, Inc. is a clinical-stage biotechnology company based in Los Angeles, California, focused on improving human health through the development of targeted antimicrobials.
Omnix Medical is a biopharmaceutical company that develops novel antibiotic agents and antimicrobial peptides to treat infections caused by drug-resistant bacteria. The company focuses on creating first-in-its-class anti-infective therapeutics, such as its lead compound OMN6, to target life-threatening bacterial strains.
Akagera Medicines is a private Delaware-registered company headquartered in Boston, Massachusetts. The company develops novel and patented liposomal formulations of antibacterial drugs.
Centivax is a privately held, clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on accelerating the transition to a post-pathogen world by developing broad-spectrum vaccines, COVID-19 therapeutics, and antivenom antibodies.
Get Bugworks Research, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Bugworks Research, Inc. in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- 8 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access